Participated · Series C · May 2026

Cerevance uses a proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify drug targets expressed in specific human brain cell types. Its lead investigational candidate, solengepras (CVN424), is a once-daily oral therapy being evaluated in the pivotal Phase 3 ARISE trial, which is fully enrolled with 341 patients. ARISE is a randomized, double-blind, placebo-controlled study assessing solengepras as an adjunctive therapy in patients with motor fluctuations; topline data are expected at the end of Q3 2026. The company also is developing CVN293, a selective oral inhibitor targeting THIK1 (KCNK13). Cerevance announced an oversubscribed $20 million Series C to fund operations through the ARISE readout and to advance its pipeline, extending runway into mid-2027. The company is clinical-stage and based in Boston.

Led · Series A · Apr 2026

Lighthouse Pharmaceuticals is a clinical-stage biopharmaceutical company whose lead clinical program is LHP588, an oral once-daily small-molecule therapy. LHP588 is being evaluated in the SPRING Phase 2 double-blind placebo-controlled trial in patients with P. gingivalis–positive mild to moderate Alzheimer's disease, and the trial is enrolling across the United States. The SPRING study is supported by a $49.2 million grant from the National Institute on Aging. Lighthouse plans to use proceeds from its Series A financing to advance LHP588 through the SPRING trial and to expand its pipeline. The company describes its approach as targeting a defined subset of Alzheimer's disease and aims to move LHP588 toward late-stage development.

Led · Series D · Nov 2025

Synchron is a New York City–based neurotechnology company building the Stentrode platform, an endovascular brain-computer interface (BCI) that is delivered via catheter rather than open-brain surgery. Once implanted, the device interfaces with the motor cortex through the blood vessels and wirelessly transmits neural signals that can be translated into hands-free digital commands. Ten patients with paralysis have received the Stentrode across U.S. and Australian clinical trials, demonstrating early clinical adoption. Led by founder and CEO Tom Oxley, the company plans to use newly raised capital to scale operations and advance product development. Synchron’s ultimate goal is to commercialize a clinically viable, minimally invasive BCI for widespread medical use. Including the latest round, the company has secured $345 million in total funding to date, underlining strong investor confidence in its technology and market potential.

Led · Series C · Jan 2025

Umoja Biopharma is a clinical-stage biotechnology company developing in vivo cell therapies to expand the reach, effectiveness, and access of CAR T treatments. Its VivoVec™ in vivo gene delivery technology is designed to empower a patient’s own immune system to fight disease by delivering therapeutic constructs directly in vivo. The company’s lead program is CD22 UB-VV400, which it plans to advance in multiple oncology and autoimmune clinical studies. Umoja intends to use proceeds from its recent financing to advance this in vivo CAR T pipeline. The company is led by CEO Andrew Scharenberg and is based in Seattle, Washington. In conjunction with the financing, Umoja added Campbell Murray, M.D., as a new board member. Umoja Biopharma leverages proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for solid tumors and hematologic malignancies. Its platform includes CAR T-cell adapter-mediated tumor-targeting (TumorTag) and in vivo modification of immune cells (VivoVec and RACR/CAR). The company’s two lead programs are TumorTag UB-TT170 for folate receptor-expressing solid tumors and VivoVec UB-VV100 for CD19+ hematological cancers. Umoja will use proceeds from a $210M Series B to continue development of its integrated technologies and advance these product candidates into clinical development. The company also plans to build internal manufacturing capabilities to support preclinical and clinical development and to expand its team. Recent leadership hires include Nushmia Khokhar as Chief Medical Officer, Irena Melnikova as Chief Financial Officer and David Fontana as Chief Business and Strategy Officer, and Umoja is establishing a manufacturing operations site in Boulder, Colorado. Umoja Biopharma is a Seattle-based, pre-clinical biotechnology company pioneering an integrated in vivo immunotherapy platform. Its platform combines three core components: the VivoVec delivery platform, RACR/CAR payload architecture, and the TumorTag platform. VivoVec acts in vivo to generate a population of cancer-fighting VivoCAR T cells that can be controlled by the RACR/CAR system using exogenously administered, FDA-approved drugs. TumorTag molecules can be used in combination with VivoCAR T cells to direct cancer-killing T cells to tumors and their critical supporting cells. Led by co-founders Andy Scharenberg, M.D., and Michael Jensen, M.D., the company aims to re-engineer a patient's immune system to attack both hematologic and solid organ-based tumors with simplicity and cost that enable widespread implementation. The $53M Series A financing will enable Umoja to advance its platform and therapeutic programs to early clinical development, attract talent and invest in research.

Led · Seed · Dec 2024

GEMMABio focuses on accelerating gene therapy research and product development to bring advanced therapies for rare diseases from bench to bedside more quickly and affordably. The company provides research and product development functions and is led by gene therapy pioneer Dr. Jim Wilson and a team formerly working in academia. Since its launch on October 1, 2024, GEMMABio has several active programs and has announced a collaboration with Fiocruz in Brazil. The company says it is building momentum and is actively seeking strategic partners to support development and global access. Financially, GEMMABio completed a $34 million seed funding round to support operational expansion and its gene therapy programs. The company emphasizes a patient-centered approach and intends to use the new capital to accelerate development and delivery of therapies worldwide.